NEW YORK (GenomeWeb News) – PerkinElmer today announced the pricing of a $500 million offering to be used in part to fund its $600 million purchase of Caliper Life Sciences.
The senior notes carry an aggregate principal amount of 5 percent and are due 2021 at an issue price of 99.372 percent of the principal amount. The issuance of the notes is expected to close Oct. 25. The notes will pay interest on a semi-annual basis.
The joint book-running managers on the offering are Merrill Lynch, Pierce, Fenner & Smith; Barclays Capital; and Deutsche Bank Securities.
The purchase of Caliper was announced last month. Earlier this week, the deal cleared regulatory hurdles in the US and Germany and now awaits shareholder approval and other conditions.